Solutions OP Clinical Trials UK

di Olga Peycheva

This podcast is dedicated to clinical trials and clinical research. We will be discussing different hot topics and analysis of the latest developments in clinical trials in pharmaceutical and medical devices industries.

Episodi del podcast

  • Clinical Trials: The UK Budget And Contracts Process

    Clinical Trials: The UK Budget And Contracts Process

    This episode is dedicated to the budget and contract process for clinical trials in the UK. The main topic is what is the current process, what works and what doesn't and how we can improve it.

  • Clinical Trials - Failure By Protocol Design

    Clinical Trials - Failure By Protocol Design

    Can a clinical trial fail because of poor protocol design? You can learn the answer in this episode which reviews a real life case of a clinical trial which failed because of its protocol design.

  • The Challenges And Benefits Of Involving Patients In Industry Sponsored Research

    The Challenges And Benefits Of Involving Patients In Industry Sponsored Research

    This episode is about patients' involvement in clinical trials and the challenges and benefits for the industry of involving patients in the study design and review of patient facing materials. While it is easy to engage patients in academic and social research, there are some unique challenges for pharma and biotech companies.

  • The Challenges Facing The Research Ethics Committees

    The Challenges Facing The Research Ethics Committees

    This episode is about the Research Ethics Committees in Europe and some of the challenges that they will face in the future. It also covers some of the existing challenges that everyone in the biotech and drug development industry faces when dealing with Ethics Committees. At the end, as always, there will be some recommendations how to improve the current practices and address the challenges.

  • What's Wrong With The UK Extended Access Program?

    What's Wrong With The UK Extended Access Program?

    The extended access scheme allows patients to have early access to drugs which are not approved on the market but have shown potential in clinical trials. In the UK for the last 10 years were treated over 1,200 patients while in the USA just in 2022 were treated 2,417 patients. Why is that difference? You can learn more from this episode and what could be done to improve access to medications to more patients in the UK.